Cargando…
Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment
PURPOSE: With the advance of screening techniques, there is a growing number of low-risk or intermediate-risk prostate cancer (PCa) cases, remaining a serious threat to men’s health. To obtain better efficacy, a growing interest has been attracted to develop such emerging treatments as immunotherapy...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052122/ https://www.ncbi.nlm.nih.gov/pubmed/33880023 http://dx.doi.org/10.2147/IJN.S301552 |
_version_ | 1783679862582542336 |
---|---|
author | Lin, Wenfeng Li, Chaoming Xu, Naijin Watanabe, Masami Xue, Ruizhi Xu, Abai Araki, Motoo Sun, Ruifen Liu, Chunxiao Nasu, Yasutomo Huang, Peng |
author_facet | Lin, Wenfeng Li, Chaoming Xu, Naijin Watanabe, Masami Xue, Ruizhi Xu, Abai Araki, Motoo Sun, Ruifen Liu, Chunxiao Nasu, Yasutomo Huang, Peng |
author_sort | Lin, Wenfeng |
collection | PubMed |
description | PURPOSE: With the advance of screening techniques, there is a growing number of low-risk or intermediate-risk prostate cancer (PCa) cases, remaining a serious threat to men’s health. To obtain better efficacy, a growing interest has been attracted to develop such emerging treatments as immunotherapy and focal therapy. However, few studies offer guidance on whether and how to combine these modalities against PCa. This study was designed to develop dual-functional nanoparticles (NPs) which combined photothermal therapy (PTT) with immunotherapy and determine the anti-tumor efficacy for PCa treatment. METHODS: By a double emulsion technique, the drug nanocarrier, poly(lactic-co-glycolic acid) or PLGA, was applied for co-loading of a fluorescent dye, indocyanine green (ICG) and a toll-like receptor 7/8 (TLR7/8) agonist resiquimod (R848) to synthesize PLGA-ICG-R848 NPs. Next, we determined their characteristic features and evaluated whether they inhibited the cell viability in multiple PCa cell lines. After treatment with PLGA-ICG-R848, the maturation markers of bone marrow-derived dendritic cells (BMDCs) were detected by flow cytometry. By establishing a subcutaneous xenograft model of mouse PCa, we explored both the anti-tumor effect and immune response following the NPs-based laser ablation. RESULTS: With a mean diameter of 157.7 nm, PLGA-ICG-R848 exhibited no cytotoxic effect in PCa cells, but they significantly decreased RM9 cell viability to (3.9±1.0)% after laser irradiation. Moreover, PLGA-ICG-R848 promoted BMDCs maturation with the significantly elevated proportions of CD11c+CD86+ and CD11c+CD80+ cells. Following PLGA-ICG-R848-based laser ablation in vivo, the decreased bioluminescent signals indicated a significant inhibition of PCa growth, while the ratio of splenic natural killer (NK) cells in PLGA-ICG-R848 was (3.96±1.88)% compared with (0.99±0.10)% in PBS group, revealing the enhanced immune response against PCa. CONCLUSION: The dual-functional PLGA-ICG-R848 NPs under laser irradiation exhibit the anti-tumor efficacy for PCa treatment by combining PTT with immunotherapy. |
format | Online Article Text |
id | pubmed-8052122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-80521222021-04-19 Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment Lin, Wenfeng Li, Chaoming Xu, Naijin Watanabe, Masami Xue, Ruizhi Xu, Abai Araki, Motoo Sun, Ruifen Liu, Chunxiao Nasu, Yasutomo Huang, Peng Int J Nanomedicine Original Research PURPOSE: With the advance of screening techniques, there is a growing number of low-risk or intermediate-risk prostate cancer (PCa) cases, remaining a serious threat to men’s health. To obtain better efficacy, a growing interest has been attracted to develop such emerging treatments as immunotherapy and focal therapy. However, few studies offer guidance on whether and how to combine these modalities against PCa. This study was designed to develop dual-functional nanoparticles (NPs) which combined photothermal therapy (PTT) with immunotherapy and determine the anti-tumor efficacy for PCa treatment. METHODS: By a double emulsion technique, the drug nanocarrier, poly(lactic-co-glycolic acid) or PLGA, was applied for co-loading of a fluorescent dye, indocyanine green (ICG) and a toll-like receptor 7/8 (TLR7/8) agonist resiquimod (R848) to synthesize PLGA-ICG-R848 NPs. Next, we determined their characteristic features and evaluated whether they inhibited the cell viability in multiple PCa cell lines. After treatment with PLGA-ICG-R848, the maturation markers of bone marrow-derived dendritic cells (BMDCs) were detected by flow cytometry. By establishing a subcutaneous xenograft model of mouse PCa, we explored both the anti-tumor effect and immune response following the NPs-based laser ablation. RESULTS: With a mean diameter of 157.7 nm, PLGA-ICG-R848 exhibited no cytotoxic effect in PCa cells, but they significantly decreased RM9 cell viability to (3.9±1.0)% after laser irradiation. Moreover, PLGA-ICG-R848 promoted BMDCs maturation with the significantly elevated proportions of CD11c+CD86+ and CD11c+CD80+ cells. Following PLGA-ICG-R848-based laser ablation in vivo, the decreased bioluminescent signals indicated a significant inhibition of PCa growth, while the ratio of splenic natural killer (NK) cells in PLGA-ICG-R848 was (3.96±1.88)% compared with (0.99±0.10)% in PBS group, revealing the enhanced immune response against PCa. CONCLUSION: The dual-functional PLGA-ICG-R848 NPs under laser irradiation exhibit the anti-tumor efficacy for PCa treatment by combining PTT with immunotherapy. Dove 2021-04-12 /pmc/articles/PMC8052122/ /pubmed/33880023 http://dx.doi.org/10.2147/IJN.S301552 Text en © 2021 Lin et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lin, Wenfeng Li, Chaoming Xu, Naijin Watanabe, Masami Xue, Ruizhi Xu, Abai Araki, Motoo Sun, Ruifen Liu, Chunxiao Nasu, Yasutomo Huang, Peng Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment |
title | Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment |
title_full | Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment |
title_fullStr | Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment |
title_full_unstemmed | Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment |
title_short | Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment |
title_sort | dual-functional plga nanoparticles co-loaded with indocyanine green and resiquimod for prostate cancer treatment |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052122/ https://www.ncbi.nlm.nih.gov/pubmed/33880023 http://dx.doi.org/10.2147/IJN.S301552 |
work_keys_str_mv | AT linwenfeng dualfunctionalplgananoparticlescoloadedwithindocyaninegreenandresiquimodforprostatecancertreatment AT lichaoming dualfunctionalplgananoparticlescoloadedwithindocyaninegreenandresiquimodforprostatecancertreatment AT xunaijin dualfunctionalplgananoparticlescoloadedwithindocyaninegreenandresiquimodforprostatecancertreatment AT watanabemasami dualfunctionalplgananoparticlescoloadedwithindocyaninegreenandresiquimodforprostatecancertreatment AT xueruizhi dualfunctionalplgananoparticlescoloadedwithindocyaninegreenandresiquimodforprostatecancertreatment AT xuabai dualfunctionalplgananoparticlescoloadedwithindocyaninegreenandresiquimodforprostatecancertreatment AT arakimotoo dualfunctionalplgananoparticlescoloadedwithindocyaninegreenandresiquimodforprostatecancertreatment AT sunruifen dualfunctionalplgananoparticlescoloadedwithindocyaninegreenandresiquimodforprostatecancertreatment AT liuchunxiao dualfunctionalplgananoparticlescoloadedwithindocyaninegreenandresiquimodforprostatecancertreatment AT nasuyasutomo dualfunctionalplgananoparticlescoloadedwithindocyaninegreenandresiquimodforprostatecancertreatment AT huangpeng dualfunctionalplgananoparticlescoloadedwithindocyaninegreenandresiquimodforprostatecancertreatment |